Paragon Associates & Paragon Associates Ii Joint Venture Dia Medica Therapeutics Inc. Transaction History
Paragon Associates & Paragon Associates Ii Joint Venture
- $39.7 Million
- Q1 2025
A detailed history of Paragon Associates & Paragon Associates Ii Joint Venture transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Paragon Associates & Paragon Associates Ii Joint Venture holds 600,000 shares of DMAC stock, worth $2.47 Million. This represents 5.72% of its overall portfolio holdings.
Number of Shares
600,000
Previous 514,784
16.55%
Holding current value
$2.47 Million
Previous $2.72 Million
16.49%
% of portfolio
5.72%
Previous 6.41%
Shares
6 transactions
Others Institutions Holding DMAC
# of Institutions
62Shares Held
6.06MCall Options Held
14.9KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.35MShares$5.55 Million0.0% of portfolio
-
First Manhattan CO New York, NY606KShares$2.49 Million0.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$2.29 Million0.0% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.57 Million0.5% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny337KShares$1.38 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $109M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...